Latest Regulatory Approvals News

Solstice Minerals has secured the advanced Nanadie Copper-Gold Project in Western Australia, acquiring a JORC-compliant Inferred Mineral Resource of 40.4Mt at 0.4% copper and 0.1g/t gold. The acquisition positions Solstice for growth amid strong long-term copper demand.

A new peer-reviewed study highlights Cynata Therapeutics’ Cymerus™ iPSC-derived MSCs as superior to traditional donor tissue-derived MSCs in potency, consistency, and regenerative potential.

The Federal Court of Australia has approved SEQ Hospitality Group’s acquisition of Eumundi Group, setting the stage for a $1.62 per share cash payout to shareholders and imminent suspension of Eumundi’s ASX trading.

A1 Investments & Resources Ltd reported a modest cash outflow for the December quarter while actively pursuing acquisition opportunities backed by secured funding. The company aims to finalize a deal soon, contingent on shareholder and regulatory approvals.

Bio-Gene Technology Limited has secured A$3 million in U.S. Department of Defense grants to accelerate development of its two nature-derived insecticides, Flavocide and Qcide, targeting both military and civilian markets.

AustChina Holdings has entered a binding agreement to acquire Penwortham Exploration, gaining access to promising gold-antimony and base metals projects in Tasmania’s prolific mining districts. The move positions AustChina to leverage modern exploration techniques on historically rich targets.

Wellnex Life has secured Therapeutic Goods Administration approval for its Liquid Paracetamol plus Caffeine Soft Gel, marking its fourth market authorisation and opening new revenue avenues.

Rimfire Pacific Mining has confirmed the Currajong Prospect as a promising new high-grade scandium opportunity, supported by historic drill data. The company plans an extensive drilling campaign in early 2025 to further define this resource within its Fifield project portfolio.

OncoSil Medical has secured authorization for 120 German hospitals to negotiate funding for its pancreatic cancer treatment device, marking a 43% increase from last year and signaling growing acceptance in Germany’s healthcare system.

Cue Energy Resources has pushed back the deadline for its gas supply agreement with Arafura from early February to the end of March 2025, signaling a critical timeline shift for the Nolans rare earths project.

Alterity Therapeutics has raised over A$2 million through its U.S. ATM facility and expects nearly A$5.7 million in Australian tax rebates, fueling the advancement of its lead neurodegenerative drug candidate ATH434 following promising Phase 2 results.

Yojee has formed a strategic joint venture with SmartClear to integrate advanced customs technology into its MOSAIC platform, supported by an oversubscribed $3.5 million capital raise aimed at fast-tracking growth in Australia and New Zealand.